The COVID-19 pandemic is halting and slowing down clinical trials, and the Food and Drug Administration is offering guidelines to adjust to these new challenges. Clinical trials may slow, stop or ...
If followed, clinical trial protocols established during the COVID-19 pandemic could allow more patients participate. The COVID-19 pandemic caused a major shift in the way that health care was ...
ACT Brief: Trial Data Transparency, Protocol Design Drives Enrollment, FDA Shifts Approval Standards
In today's ACT Brief, we examine why transparency in complex trial designs is essential for data confidence, how protocol structure—not operational effort—determines recruitment success, and the FDA's ...
See IQVIA’s new AI‑driven capabilities in the Clinical Trial Financial Suite (CTFS) in action—featuring live demos of CTFS Site Payments and Protocol Ingestion for CTFS GrantPlan. Learn how these ...
ClinCapture President and CEO Scott Weidley today announced a major expansion of artificial intelligence capabilities within the company's Captivate® platform, embedding AI directly into the ...
Clinical trials are increasing in complexity at the same time as clinical development teams are being tasked with doing more with less. This panel of experts address why and how protocol complexity ...
When discussing the future of clinical trials, people often focus on the promise of exciting new technologies, including artificial intelligence (AI) and predictive modeling. However, even the most ...
Method of treatment patents based on Phase II and Phase III clinical trial protocols are routinely pursued to extend patent exclusivity and strategically build a patent portfolio for a drug asset. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results